TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The role of transforming growth factor beta (TGFbeta) in tumor progression is context-dependent, exhibiting pro-angiogenic and tumor-promoting effects in later stages.
• While TGFbeta can inhibit early tumor development, its late-stage activities are crucial for tumor growth and metastasis.

Purpose of the Study:

• To investigate the pro-angiogenic effects of TGFbeta on human microvascular endothelial cells (MVEC) in vitro.
• To evaluate the efficacy of TGFbeta antagonist peptides in blocking TGFbeta-induced angiogenesis and associated signaling pathways.
• To assess the in vivo anti-angiogenic potential of these inhibitors.

Main Methods:

• MVEC cultures treated with TGFbeta to assess invasion and capillary morphogenesis.
• RT-PCR analysis to determine gene expression changes (PAI-1, uPAR).
• Western blotting to analyze SMAD2/3 and FAK signaling pathway activation.
• In vitro and in vivo (Matrigel Sponge Assay) testing of TGFbeta antagonist peptides.

Main Results:

• TGFbeta significantly promoted MVEC invasion and capillary-like structure formation, with no observed apoptotic activity.
• TGFbeta upregulated the expression of plasminogen activator inhibitor type-1 (PAI-1) and urokinase-type plasminogen activator receptor (uPAR).
• TGFbeta antagonist peptides inhibited TGFbeta-induced signaling pathways (SMAD2/3, FAK), pro-angiogenic responses, and PAI-1/uPAR upregulation in MVEC, demonstrating anti-angiogenic effects both in vitro and in vivo.

Conclusions:

• TGFbeta plays a significant role in promoting angiogenesis in late-stage tumor progression.
• TGFbeta antagonist peptides effectively inhibit TGFbeta-mediated angiogenesis by targeting key signaling pathways and downstream effectors like uPAR and PAI-1.
• These findings support the development of TGFbeta antagonist peptides as a therapeutic strategy for combating angiogenesis in late-stage cancers.